MannKind | MNKD - Selling And Administration Expenses


MannKind reported $29.09M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Adma Biologics USD 23.05M 320K Sep/2025
Dynavax Technologies USD 40.09M 1.45M Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Halozyme Therapeutics USD 37.53M 4.53M Sep/2025
Insmed USD 186.38M 109.94M Sep/2025
MacroGenics USD 9.9M 600K Sep/2025
MannKind USD 29.09M 2.53M Sep/2025
Merck USD 2.63B 0 Sep/2025
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pfizer USD 3.19B 209M Sep/2025
Sanofi EUR 2.75B 455M Dec/2025
Xencor USD 87.78M 72.66M Sep/2025